A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

ClinicalTrials.gov ID: NCT03766685

Public ClinicalTrials.gov record NCT03766685. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 18, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study identification

NCT ID: NCT03766685
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: UCB Biopharma SRL; Industry
Enrollment: 172 participants

Conditions and interventions

Conditions

Interventions

Bimekizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 19, 2018
Primary completion: Jul 13, 2020
Completion: Sep 7, 2020
Last update posted: Jul 13, 2025

2018 – 2020

United States locations

U.S. sites: 27
U.S. states: 18
U.S. cities: 26

Facility	City	State	ZIP	Site status
Dv0002 946	Phoenix	Arizona	85032	—
Dv0002 910	Bakersfield	California	93309	—
Dv0002 955	San Diego	California	92123	—
Dv0002 943	San Luis Obispo	California	93405	—
Dv0002 967	Santa Monica	California	90404	—
Dv0002 906	Boca Raton	Florida	33486	—
Dv0002 907	Miami	Florida	33144	—
Dv0002 903	Ocala	Florida	34471	—
Dv0002 936	Tampa	Florida	33624	—
Dv0002 941	Alpharetta	Georgia	30022	—
Dv0002 954	Skokie	Illinois	60077	—
Dv0002 900	West Des Moines	Iowa	50265	—
Dv0002 905	Overland Park	Kansas	66215	—
Dv0002 962	Owensboro	Kentucky	42301	—
Dv0002 922	Baton Rouge	Louisiana	70809	—
Dv0002 925	Brighton	Massachusetts	02135	—
Dv0002 917	Troy	Michigan	48084	—
Dv0002 915	St Louis	Missouri	63117	—
Dv0002 901	Portsmouth	New Hampshire	03801	—
Dv0002 908	East Windsor	New Jersey	08520	—
Dv0002 913	New York	New York	10029	—
Dv0002 963	Rochester	New York	14623	—
Dv0002 920	Portland	Oregon	97210	—
Dv0002 929	Portland	Oregon	97223	—
Dv0002 937	Johnston	Rhode Island	02919	—
Dv0002 951	Houston	Texas	77598	—
Dv0002 914	San Antonio	Texas	78213	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03766685, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 13, 2025 · Synced May 18, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03766685 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →